Cited by 1,076Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesHIV, Drug Use, Sexual Risk

The DOI matches its Crossref record; 34 of the 38 references it cites were found in a registry or an index.

Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study

Open access

Larochelle, Marc R., Bernson, Dana, Land, Thomas, Stopka, Thomas J., Wang, Na, Xuan, Ziming, Bagley, Sarah M., Liebschutz, Jane M., Walley, Alexander Y.·2018·Annals of Internal Medicine

DOI 10.7326/m17-3107PMC PMC6387681

Open this paper in CoChat — free account

Abstract

Background: Opioid overdose survivors have an increased risk for death. Whether use of medications for opioid use disorder (MOUD) after overdose is associated with mortality is not known. Objective: To identify MOUD use after opioid overdose and its association with all-cause and opioid-related mortality. Design: Retrospective cohort study. Setting: 7 individually linked data sets from Massachusetts government agencies. Participants: 17 568 Massachusetts adults without cancer who survived an opioid overdose between 2012 and 2014. Measurements: Three types of MOUD were examined: methadone maintenance treatment (MMT), buprenorphine, and naltrexone. Exposure to MOUD was identified at monthly intervals, and persons were considered exposed through the month after last receipt. A multivariable Cox proportional hazards model was used to examine MOUD as a monthly time-varying exposure variable to predict time to all-cause and opioid-related mortality. Results: In the 12 months after a nonfatal overdose, 2040 persons (11%) enrolled in MMT for a median of 5 months (interquartile range, 2 to 9 months), 3022 persons (17%) received buprenorphine for a median of 4 months (interquartile range, 2 to 8 months), and 1099 persons (6%) received naltrexone for a median of 1 month (interquartile range, 1 to 2 months). Among the entire cohort, all-cause mortality was 4.7 deaths (95% CI, 4.4 to 5.0 deaths) per 100 person-years and opioid-related mortality was 2.1 deaths (CI, 1.9 to 2.4 deaths) per 100 person-years. Compared with no MOUD, MMT was associated with decreased all-cause mortality (adjusted hazard ratio [AHR], 0.47 [CI, 0.32 to 0.71]) and opioid-related mortality (AHR, 0.41 [CI, 0.24 to 0.70]). Buprenorphine was associated with decreased all-cause mortality (AHR, 0.63 [CI, 0.46 to 0.87]) and opioid-related mortality (AHR, 0.62 [CI, 0.41 to 0.92]). No associations between naltrexone and all-cause mortality (AHR, 1.44 [CI, 0.84 to 2.46]) or opioid-related mortality (AHR, 1.42 [CI, 0.73 to 2.79]) were identified. Limitation: Few events among naltrexone recipients preclude confident conclusions. Conclusion: A minority of opioid overdose survivors received MOUD. Buprenorphine and MMT were associated with reduced all-cause and opioid-related mortality. Primary Funding Source: National Center for Advancing Translational Sciences of the National Institutes of Health.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.7326/m17-3107

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sensitivity analysis in observational research: Introducing the E-value
VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C. L., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,312
Increases in drug and opioid-involved overdose deaths – United States, 2010-2015
Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm655051e1 · Cited by 2,194
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654
Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402780 · Cited by 1,014
Emergency Department–Initiated Buprenorphine/Naloxone Treatment for Opioid Dependence
D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015) · JAMA · doi:10.1001/jama.2015.3474 · Cited by 913
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial
Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial
Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60358-9 · Cited by 555
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C. L., Kimber, J., Davoli, M., & Breen, R. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209 · Cited by 536

Flagged first, then by citations

Show all 38 references

4 of the 38 references couldn’t be matched to a known paper.

Sorted by citations

CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7103a1 · Cited by 1,886
Comparative effectiveness of different treatment pathways for opioid use disorder.
Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.20622 · Cited by 995
Self-citation
Opioid use disorder
Strang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0137-5 · Cited by 639
Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence
Santo, T., Clark, B., Hickman, M., Grebely, J., Campbell, G., Sordo, L., Chen, A. B., Tran, L. T., Bharat, C., Padmanathan, P., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0976 · Cited by 614
Prevention and Treatment of Opioid Misuse and Addiction: A Review
Volkow, N. D., Jones, E. B., Einstein, E. B., & Wargo, E. M. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3126 · Cited by 596
Stigma as a fundamental hindrance to the United States opioid overdose crisis response
Tsai, A. C., Kiang, M. V., Barnett, M. L., Beletsky, L. A., Keyes, K. M., McGinty, E. E., Smith, L. R., Strathdee, S. A., Wakeman, S. E., & Venkataramani, A. S. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002969 · Cited by 460
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update
(2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000633 · Cited by 412
Development of a Cascade of Care for responding to the opioid epidemic.
Williams, A. R., Nunes, E. V., Bisaga, A., Levin, F. R., & Olfson, M. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1546862 · Cited by 332
Telemedicine-delivered treatment interventions for substance use disorders: A systematic review
Lin, L. (., Casteel, D., Shigekawa, E., Weyrich, M. S., Roby, D. H., & McMenamin, S. B. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.03.007 · Cited by 291
Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States
Goedel, W. C., Shapiro, A. M., Cerdá, M., Tsai, J. W., Hadland, S. E., & Marshall, B. D. L. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.3711 · Cited by 310
Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States
Chen, Q., Larochelle, M. R., Weaver, D. T., Lietz, A. P., Mueller, P. P., Mercaldo, S., Wakeman, S. E., Freedberg, K. A., Raphel, T. J., Knudsen, A. B., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.7621 · Cited by 273
Self-citation
Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder
Haffajee, R. L., Lin, L. A., Bohnert, A. S. B., & Goldstick, J. E. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.6373 · Cited by 266
Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers Within the Treatment System
Madras, B. K., Ahmad, N. J., Wen, J., Sharfstein, J., & Prevention, T. (2020) · NAM Perspectives · doi:10.31478/202004b · Cited by 258
Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019
Mauro, P. M., Gutkind, S., Annunziato, E. M., & Samples, H. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.3821 · Cited by 226
The opioid crisis: a contextual, social-ecological framework
Jalali, M. S., Botticelli, M. P., Hwang, R. C., Koh, H. K., & McHugh, R. K. (2020) · Health Research Policy and Systems · doi:10.1186/s12961-020-00596-8 · Cited by 242
Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder
Williams, A. R., Samples, H., Crystal, S., & Olfson, M. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19060612 · Cited by 211
Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study
Pearce, L. A., Min, J. E., Piske, M., Zhou, H., Homayra, F., Slaunwhite, A., Irvine, M. A., McGowan, G., & Nosyk, B. (2020) · BMJ · doi:10.1136/bmj.m772 · Cited by 208
Touchpoints—opportunities to predict and prevent opioid overdose: a cohort study.
Larochelle, M. R., Bernstein, R., Bernson, D., Land, T., Stopka, T. J., Rose, A. J., Bharel, M., Liebschutz, J. M., & Walley, A. Y. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.06.039 · Cited by 189
“More specifically, studies among overdose survivors and individuals released from incarceration have shown MOUD are associated with reduced opioid overdose death yet a minority receive them (Green et al., 2018; Larochelle et al., 2018).”
BackgroundMethodSelf-citation
A conceptual model for understanding post-release opioid-related overdose risk
Joudrey, P. J., Khan, M. R., Wang, E. A., Scheidell, J. D., Edelman, E. J., McInnes, D. K., & Fox, A. D. (2019) · Addiction Science & Clinical Practice · doi:10.1186/s13722-019-0145-5 · Cited by 208
Barriers and Facilitators to Clinician Readiness to Provide Emergency Department–Initiated Buprenorphine
Hawk, K. F., D’Onofrio, G., Chawarski, M. C., O’Connor, P. G., Cowan, E. A., Lyons, M. S., Richardson, L. D., Rothman, R. E., Whiteside, L., Owens, P. H., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.4561 · Cited by 182
Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts
Schiff, D. M., Nielsen, T. C., Hoeppner, B. B., Terplan, M., Hansen, H., Bernson, D., Diop, H., Bharel, M., Krans, E. E., Selk, S., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.5734 · Cited by 179
Self-citation
Opioid agonist treatment and fatal overdose risk in a state‐wide US population receiving opioid use disorder services
Krawczyk, N., Mojtabai, R., Stuart, E. A., Fingerhood, M., Agus, D., Lyons, B. C., Weiner, J. P., & Saloner, B. (2020) · Addiction · doi:10.1111/add.14991 · Cited by 177
Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review
Madden, E. F., Prevedel, S. M., Light, T., & Sulzer, S. H. (2021) · Substance Use & Misuse · doi:10.1080/10826084.2021.1975749 · Cited by 178
A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain
Gudin, J. A., & Fudin, J. (2020) · Pain and Therapy · doi:10.1007/s40122-019-00143-6 · Cited by 180
Keeping Up with Clinical Advances: Opioid Use Disorder
Patel, B., & Kosten, T. R. (2019) · CNS Spectrums · doi:10.1017/s109285291900110x · Cited by 165
Public policy and health in the Trump era
Woolhandler, S. J., Himmelstein, D. U., Ahmed, S., Bailey, Z., Bassett, M. T., Bird, M. E., Bor, J. H., Bor, D. H., Carrasquillo, O., Chowkwanyun, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32545-9 · Cited by 172
The Effect of Overdose Education and Naloxone Distribution: An Umbrella Review of Systematic Reviews
Razaghizad, A., Windle, S. B., Filion, K. B., Gore, G. C., Kudrina, I., Paraskevopoulos, E., Kimmelman, J., Martel, M. O., & Eisenberg, M. J. (2021) · American Journal of Public Health · doi:10.2105/ajph.2021.306306 · Cited by 190
Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort
Morgan, J. R., Schackman, B. R., Weinstein, Z. M., Walley, A. Y., & Linas, B. P. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.02.031 · Cited by 159
Self-citation
Fentanyl shock: The changing geography of overdose in the United States
Zoorob, M. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.04.010 · Cited by 160
The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices
WALSH, S. L., El‐Bassel, N., Jackson, R. D., Samet, J. H., Aggarwal, M., Aldridge, A., Baker, T. J., Barbosa, C., Barocas, J. A., Battaglia, T. A., et al. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108335 · Cited by 157
Self-citation
Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction
Calcaterra, S. L., Bach, P., Chadi, A., Chadi, N., Kimmel, S. D., Morford, K. L., Roy, P. J., & Samet, J. H. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-018-4801-3 · Cited by 151
Opioid-Associated Out-of-Hospital Cardiac Arrest: Distinctive Clinical Features and Implications for Health Care and Public Responses: A Scientific Statement From the American Heart Association
Dezfulian, C., Orkin, A. M., Maron, B. A., Elmer, J., Girotra, S. R., Gladwin, M. T., Merchant, R. M., Panchal, A. R., Perman, S. M., Starks, M. A., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000958 · Cited by 153
Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel
Kohan, L. R., Potru, S., Barreveld, A. M., Sprintz, M., Lane, O. P., Aryal, A., Emerick, T. D., Dopp, A., Chhay, S., & Viscusi, E. R. (2021) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2021-103007 · Cited by 147
Incidence of Treatment for Opioid Use Disorder Following Nonfatal Overdose in Commercially Insured Patients
Kilaru, A. S., Xiong, R. A., Lowenstein, M., Meisel, Z. F., Perrone, J., Khatri, U. G., Mitra, N., & Delgado, M. K. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.5852 · Cited by 138
The Next Stage of Buprenorphine Care for Opioid Use Disorder
Martin, S. A., Chiodo, L. M., Bosse, J. D., & Wilson, A. (2018) · Annals of Internal Medicine · doi:10.7326/m18-1652 · Cited by 130
The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study
Winhusen, T. M., Walley, A. Y., Fanucchi, L. C., Hunt, T., Lyons, M., Lofwall, M. R., Brown, J. L., Freeman, P. R., Nunes, E. V., Beers, D., et al. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108325 · Cited by 135
Self-citation
Emergency Department Visits for Nonfatal Opioid Overdose During the COVID-19 Pandemic Across Six US Health Care Systems
Soares, W. E., Melnick, E. R., Nath, B., D’Onofrio, G., Paek, H., Skains, R. M., Walter, L. A., Casey, M. F., Napoli, A. M., Hoppe, J. A., et al. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.03.013 · Cited by 126
Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs
Rosenthal, E. S., Silk, R., Mathur, P., Gross, C., Eyasu, R., Nussdorf, L., Hill, K. C., Brokus, C. J., D’Amore, A., Sidique, N., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa105 · Cited by 126
Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department
Hawk, K. F., Hoppe, J. A., Ketcham, E. M., LaPietra, A. M., Moulin, A. K., Nelson, L. S., Schwarz, E. S., Shahid, S., Stader, D. E., Wilson, M. P., et al. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.04.023 · Cited by 125
Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018
Brown, E., Schutze, M., Taylor, A., Jorgenson, D., McGuire, C. A., Brown, A., Middleton, A., Woodcock, C., LaPres, M., Cohn, L. M., et al. (2021) · JAMA · doi:10.1001/jama.2021.7374 · Cited by 121
Prevention of Opioid Overdose
Babu, K. M., Brent, J. A., & Juurlink, D. N. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1807054 · Cited by 127
Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl
Chambers, L. C., Hallowell, B. D., Zullo, A. R., Paiva, T. J., Berk, J., Gaither, R., Hampson, A. J., Beaudoin, F. L., & Wightman, R. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.34540 · Cited by 122
Emergency Departments — A 24/7/365 Option for Combating the Opioid Crisis
D’Onofrio, G., McCormack, R. P., & Hawk, K. F. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1811988 · Cited by 119
Receipt of Addiction Treatment After Opioid Overdose Among Medicaid-Enrolled Adolescents and Young Adults
Alinsky, R. H., Zima, B. T., Rodean, J., Matson, P. A., Larochelle, M. R., Adger, H., Bagley, S. M., & Hadland, S. E. (2020) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2019.5183 · Cited by 117
Self-citation
Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study
Joudrey, P. J., Chadi, N., Roy, P. J., Morford, K. L., Bach, P., Kimmel, S. D., Wang, E. A., & Calcaterra, S. L. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107968 · Cited by 122
Risk Factors for Drug Overdose in Young People: A Systematic Review of the Literature
Lyons, R. M., Yule, A. M., Schiff, D. M., Bagley, S. M., & Wilens, T. E. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0013 · Cited by 116
Self-citation
Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco
Carter, J., Zevin, B., & Lum, P. J. (2019) · Addiction Science & Clinical Practice · doi:10.1186/s13722-019-0149-1 · Cited by 110
Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration
Lin, L. A., Bohnert, A. S. B., Blow, F. C., Gordon, A. J., Ignacio, R. V., Kim, H. M., & Ilgen, M. A. (2021) · Addiction · doi:10.1111/add.15116 · Cited by 108
Managing Opioid Withdrawal in the Emergency Department With Buprenorphine
Herring, A. A., Perrone, J., & Nelson, L. S. (2019) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2018.11.032 · Cited by 107
Role of the Hospital in the 21st Century Opioid Overdose Epidemic: The Addiction Medicine Consult Service
Priest, K. C., & McCarty, D. W. (2019) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000496 · Cited by 109
Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use
Hollander, M. A. G., Chang, C. H., Douaihy, A. B., Hulsey, E. G., & Donohue, J. M. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108927 · Cited by 107
Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality
Beetham, T., Saloner, B. K., Wakeman, S. E., Gaye, M., & Barnett, M. L. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3457 · Cited by 105
Addressing opioid overdose deaths: The vision for the HEALing communities study
Chandler, R. K., Villani, J., Clarke, T., McCance‐Katz, E. F., & Volkow, N. D. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108329 · Cited by 104
Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use–Associated Infective Endocarditis
Kimmel, S. D., Walley, A. Y., Li, Y., Linas, B. P., Lodi, S., Bernson, D., Weiss, R. D., Samet, J. H., & Larochelle, M. R. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.16228 · Cited by 104
Self-citation
Trends in Opioid Use Disorder Among Older Adults: Analyzing Medicare Data, 2013–2018
Shoff, C. M., Yang, T., & Shaw, B. A. (2021) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2021.01.010 · Cited by 103
The Impact of the Opioid Epidemic on Children and Adolescents
Winstanley, E. L., & Stover, A. N. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.06.003 · Cited by 109
Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine
Tsui, J. I., Mayfield, J., Speaker, E. C., Yakup, S., Ries, R. K., Funai, H., Leroux, B. G., & Merrill, J. O. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.10.005 · Cited by 100
Peer navigation and take-home naloxone for opioid overdose emergency department patients: Preliminary patient outcomes
Samuels, E. A., Bernstein, S. L., Marshall, B. D. L., Krieger, M. S., Baird, J. B., & Mello, M. J. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.07.013 · Cited by 102
Opioid Use Disorder
Taylor, J. L., & Samet, J. H. (2022) · Annals of Internal Medicine · doi:10.7326/aitc202201180 · Cited by 102
National U.S. time-trends in opioid use disorder hospitalizations and associated healthcare utilization and mortality
Singh, J. A., & Cleveland, J. D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229174 · Cited by 98
Predictors of Overdose Death Among High-Risk Emergency Department Patients With Substance-Related Encounters: A Data Linkage Cohort Study
Krawczyk, N., Eisenberg, M. D., Schneider, K. E., Richards, T. M., Lyons, B. C., Jackson, K., Ferris, L. M., Weiner, J. P., & Saloner, B. K. (2019) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.07.014 · Cited by 93
Peer recovery coaches in general medical settings: Changes in utilization, treatment engagement, and opioid use
Magidson, J. F., Regan, S., Powell, E., Jack, H. E., Herman, G. E., Zaro, C., Kane, M. T., & Wakeman, S. E. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108248 · Cited by 93
Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings
Taylor, J. L., Johnson, S., Cruz, R., Gray, J. R., Schiff, D. M., & Bagley, S. M. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-06904-4 · Cited by 94
Self-citation
Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?
Carlson, R. G., Daniulaityte, R., Silverstein, S. M., Nahhas, R. W., & Martins, S. S. (2020) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2020.102722 · Cited by 90
Rapid Adoption of Low-Threshold Buprenorphine Treatment at California Emergency Departments Participating in the CA Bridge Program
Snyder, H. R., Kalmin, M. M., Moulin, A. K., Campbell, A., Goodman‐Meza, D., Padwa, H., Clayton, S., Speener, M., SHOPTAW, S. J., & Herring, A. A. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.05.024 · Cited by 94
Changing Trends in Opioid Overdose Deaths and Prescription Opioid Receipt Among Veterans
Lin, L. (., Peltzman, T., McCarthy, J. F., Oliva, E. M., Trafton, J. A., & Bohnert, A. S. B. (2019) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2019.01.016 · Cited by 90
Opioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concern
Alho, H., Demattéis, M., Lembo, D., Maremmani, I., Roncero, C., & Somaini, L. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.102616 · Cited by 90
The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
Aquino, J. P. D., Parida, S., & Sofuoglu, M. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01032-7 · Cited by 89
Structural Racism and the Opioid Overdose Epidemic: The Need for Antiracist Public Health Practice
Kunins, H. V. (2020) · Journal of Public Health Management and Practice · doi:10.1097/phh.0000000000001168 · Cited by 90
Underutilization of Medications to Treat Opioid Use Disorder: What Role Does Stigma Play?
Allen, B., Nolan, M. L., & Paone, D. (2019) · Substance Abuse · doi:10.1080/08897077.2019.1640833 · Cited by 85
Measurement‐based care using DSM‐5 for opioid use disorder: can we make opioid medication treatment more effective?
Marsden, J., Tai, B., Ali, R. L., Hu, L., Rush, A. J., & Volkow, N. D. (2019) · Addiction · doi:10.1111/add.14546 · Cited by 80
The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network
Marsch, L. A., Campbell, A. N. C., Campbell, C. I., Chen-Ritzo, C.-H., Ertin, E., Ghitza, U. E., Lambert-Harris, C. A., Hassanpour, S., Holtyn, A. F., Hser, Y., et al. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.02.005 · Cited by 88
Methadone Access for Opioid Use Disorder During the COVID-19 Pandemic Within the United States and Canada
Joudrey, P. J., Adams, Z. M., Bach, P., Buren, S. V., Chaiton, J. A., Ehrenfeld, L., Guerra, M. E., Gleeson, B., Kimmel, S. D., Medley, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.18223 · Cited by 79
Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine
Park, T. W., Larochelle, M. R., Saitz, R., Wang, N., Bernson, D., & Walley, A. Y. (2020) · Addiction · doi:10.1111/add.14886 · Cited by 78
Self-citation
Risk of bias in observational studies using routinely collected data of comparative effectiveness research: a meta-research study
Nguyen, V. T., Engleton, M., Davison, M., Ravaud, P., Porcher, R., & Boutron, I. (2021) · BMC Medicine · doi:10.1186/s12916-021-02151-w · Cited by 82
Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths
The HEALing Communities Study Consortium (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401177 · Cited by 76
Projected estimates of opioid mortality after community-level interventions.
Linas, B. P., Savinkina, A., Madushani, R. W. M. A., Wang, J., Eftekhari Yazdi, G., Chatterjee, A., Walley, A. Y., Morgan, J. R., Epstein, R. L., Assoumou, S. A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.37259 · Cited by 72
Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol
Terasaki, D., Smith, C., & Calcaterra, S. L. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2313 · Cited by 75
Retention Strategies for Medications for Opioid Use Disorder in Adults: A Rapid Evidence Review
Chan, B. L., Gean, E. G., Arkhipova-Jenkins, I., Gilbert, J., Hilgart, J., Fiordalisi, C. V., Hubbard, K., Brandt, I., Stoeger, E., Paynter, R. A., et al. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000739 · Cited by 73
Substance use disorder bridge clinics: models, evidence, and future directions
Taylor, J. L., Wakeman, S. E., Walley, A. Y., & Kehoe, L. G. (2023) · Addiction Science & Clinical Practice · doi:10.1186/s13722-023-00365-2 · Cited by 68
Self-citation
Addiction Consultation Services for Opioid Use Disorder Treatment Initiation and Engagement
McNeely, J., Wang, S. S., Abadi, Y. R., Barron, C. T., Billings, J., Tarpey, T., Fernando, J., Appleton, N., Fawole, A., Mazumdar, M., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.3422 · Cited by 69
Multi-model implementation of evidence-based care in the treatment of opioid use disorder in Pennsylvania
Kawasaki, S. S., Francis, E. B., Mills, S., Buchberger, G., Hogentogler, R., & Kraschnewski, J. L. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.08.016 · Cited by 67
Duration of medication treatment for opioid‐use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study
Burns, M. E., Tang, L., Chang, C. H., Kim, J. Y., Ahrens, K. A., Allen, L., Cunningham, P. J., Gordon, A. J., Jarlenski, M., Lanier, P., et al. (2022) · Addiction · doi:10.1111/add.15959 · Cited by 67
Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH)
D’Onofrio, G., Edelman, E. J., Hawk, K. F., Pantalon, M. V., Chawarski, M. C., Owens, P. H., Martel, S. H., VanVeldhuisen, P., Oden, N. L., Murphy, S. M., et al. (2019) · Implementation Science · doi:10.1186/s13012-019-0891-5 · Cited by 67
Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery
Nielsen, T. C., Bernson, D., Terplan, M., Wakeman, S. E., Yule, A. M., Mehta, P., Bharel, M., Diop, H., Taveras, E. M., Wilens, T. E., et al. (2019) · Addiction · doi:10.1111/add.14825 · Cited by 65
Self-citation
Predictors of Opioid and Alcohol Pharmacotherapy Initiation at Hospital Discharge Among Patients Seen by an Inpatient Addiction Consult Service
Englander, H. L., King, C. A., Nicolaidis, C., Collins, D., Patten, A., Gregg, J. L., & Korthuis, P. T. (2019) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000611 · Cited by 64
Outcomes Associated With Medications for Opioid Use Disorder Among Persons Hospitalized for Infective Endocarditis
Barocas, J. A., Morgan, J. R., Wang, J., McLoone, D., Wurcel, A. G., & Stein, M. D. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa062 · Cited by 64
Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic
Hailu, R., Mehrotra, A., Huskamp, H. A., Busch, A. B., & Barnett, M. L. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.52381 · Cited by 63
Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA
Hill, L. G., Loera, L. J., Evoy, K. E., Renfro, M. L., Torrez, S. B., Zagorski, C. M., Perez, J. C., Jones, S., & Reveles, K. R. (2020) · Addiction · doi:10.1111/add.15314 · Cited by 62
A Quality Framework for Emergency Department Treatment of Opioid Use Disorder
Samuels, E. A., D’Onofrio, G., Huntley, K., Levin, S., Schuur, J. D., Bart, G. B., Hawk, K. F., Tai, B., Campbell, C. I., & Venkatesh, A. K. (2018) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2018.08.439 · Cited by 64
The case for a medication first approach to the treatment of opioid use disorder
Winograd, R., Presnall, N. J., Stringfellow, E. J., Wood, C. A., Horn, P., Duello, A., Green, L., & Rudder, T. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1605372 · Cited by 59
Disparities in Access to Medications for Opioid Use Disorder in the Veterans Health Administration
Finlay, A. K., Harris, A. H. S., Timko, C., Yu, M., Smelson, D. A., Stimmel, M. A., & Binswanger, I. A. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000719 · Cited by 61
Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study
Barocas, J. A., Yazdi, G. E., Savinkina, A. A., Nolen, S., Savitzky, C., Samet, J. H., Englander, H. L., & Linas, B. P. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1346 · Cited by 63
Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic
Nguyen, T. D., Ziedan, E., Simon, K. I., Miles, J., Crystal, S., Samples, H., & Gupta, S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.14765 · Cited by 59
Addressing adolescent substance use with a public health prevention framework: the case for harm reduction
Winer, J. M., Yule, A. M., Hadland, S. E., & Bagley, S. M. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2104922 · Cited by 70
Self-citation
One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission
Stone, A. C., Carroll, J. J., Rich, J. D., & Green, T. C. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108031 · Cited by 58
A Critical Review of the Social and Behavioral Contributions to the Overdose Epidemic
Cerdá, M., Krawczyk, N., Hamilton, L., Rudolph, K. E., Friedman, S. R., & Keyes, K. M. (2020) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-090419-102727 · Cited by 61
Buprenorphine Field Initiation of ReScue Treatment by Emergency Medical Services (Bupe FIRST EMS): A Case Series
Carroll, G. G., Wasserman, D. D., Shah, A., Salzman, M., Baston, K., Rohrbach, R., Jones, I., & Haroz, R. (2020) · Prehospital Emergency Care · doi:10.1080/10903127.2020.1747579 · Cited by 56
Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes, E. V., LEVIN, F. R., Reilly, M. P., & El‐Bassel, N. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108196 · Cited by 56
Inpatient Addiction Medicine Consultation Service Impact on Post-discharge Patient Mortality: a Propensity-Matched Analysis
Wilson, J. D., Dunn, S. C. A., Roy, P. J., Joseph, E., Klipp, S., & Liebschutz, J. M. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07362-8 · Cited by 56
Self-citation

Authors: Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y.
Affiliations: Boston University (US)
Massachusetts Department of Public Health (US)
Tufts University (US)
ORCID: Larochelle, Marc R.
Bernson, Dana
Stopka, Thomas J.
Wang, Na
Xuan, Ziming
Bagley, Sarah M.
Liebschutz, Jane M.
Walley, Alexander Y.
Venue: Annals of Internal Medicine
Publisher: American College of Physicians
Published: 2018-08-07
Volume: 169
Issue: 3
Pages: 137-145
ISSN: 0003-4819 (ISSN-L)
1539-3704
DOI: 10.7326/m17-3107
PMC: PMC6387681
OpenAlex: W2808907017
Cited by: 1,076
References: 38
Citations by year: 2026: 99 · 2025: 140 · 2024: 161 · 2023: 133 · 2022: 134 · 2021: 157 · 2020: 117 · 2019: 113 · 2018: 21
FWCI: 97.09
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations: Annals of Internal Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR001430)
National Institute on Drug Abuse (K23DA042168)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
Keywords: opioid use disorder, medication-assisted treatment, methadone maintenance treatment, buprenorphine, naltrexone, opioid-related deaths, all-cause mortality, opioid overdose prevention
MeSH terms: Adolescent, Adult, Analgesics, Opioid, Buprenorphine, Female, Humans, Male, Massachusetts, Methadone, Middle Aged, Mortality, Naltrexone, Opioid-Related Disorders, Retrospective Studies, Proportional Hazards Models, Young Adult, Opiate Substitution Treatment, Drug Overdose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks